– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 –
Related Questions
Are there any new partnership, licensing, or pipeline updates in the business update that could drive future growth?
How does the $10.0 million net revenue compare to Coherus Oncology's historical performance and peer benchmarks?
How might the earnings beat or miss relative to analyst expectations influence the stock's short‑term volatility?
What guidance is the company providing for future quarters and how will it affect earnings forecasts?
What is the expected impact of the Q2 results on the company's cash burn and runway?
What is the market's reaction to the 36% YoY net revenue increase for LOQTORZI in Q2 2025?
What macro or sector trends could amplify or mitigate the significance of this earnings release?